摘要
Abstract
Objective To investigate the clinical efficacy of triple therapy with rabeprazole in the treatment of helicobacter pylori ( HP ) positive peptic ulcer. Methods Totally 100 cases of HP positive peptic ulcer patients in the hospital from June 2013 to June 2016 were selected and divided into two groups according to the different treatment methods, 58 patients with rabeprazole+amoxicillin+clarithromycin were included in the observation group, 42 patients with omeprazole+amoxicillin+clarithromycin were included in the control group. The clinical efficacy, HP clearance and adverse events were observed in both groups, followed up for 6 months, the recurrence rate was collected. Results The total effective rate and HP clearance rate in the observation group were 96. 55% and 94. 83%, respectively, which were significantly higher than 80. 95% and 76. 19% in the control group ( P < 0. 05 ) , the incidence rate of adverse reactions was 18. 97% in the observation group and 26. 19% in the control group ( P > 0. 05 ) , the recurrence rate in the observation group was 6. 90%, which was significantly lower than 21. 43% in the control group ( P < 0. 05 ) . Conclusion Rabeprazole triple therapy for treating HP positive peptic ulcer has good effect, low recurrence rate, it is worth of clinical promotion.关键词
消化性溃疡/雷贝拉唑/幽门螺旋杆菌/三联疗法/临床疗效Key words
peptic ulcer/rebeprazole/helicobacter pylori/triple therapy/clinic efficacy分类
医药卫生
